Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
JANX is expected to report earnings to rise 35.40% to -47 cents per share on November 10
Q3'26
Est.
$-0.47
Q2'26
Missed
by $0.08
Q1'26
Beat
by $0.18
Q4'25
Beat
by $0.11
Q3'25
Beat
by $0.23
The last earnings report on August 06 showed earnings per share of -34 cents, missing the estimate of -27 cents. With 199.81K shares outstanding, the current market capitalization sits at 1.01B.